ACADIA Pharmaceuticals (NASDAQ:ACAD) Posts Earnings Results, Beats Estimates By $0.12 EPS

Posted by Francis Steltz on Aug 4th, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.06 by $0.12, FiscalAI reports. ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The company had revenue of $308.00 million during the quarter, compared to analyst estimates of $295.51 million. During the same quarter last year, the business posted $0.16 earnings per share. The firm’s revenue was up 16.4% on a year-over-year basis.

Here are the key takeaways from ACADIA Pharmaceuticals’ conference call:

Second-quarter revenue rose 17% to $308 million on an adjusted basis, driven by strong demand for both DAYBUE and NUPLAZID.
DAYBUE sales increased 30% to $125 million, with DAYBUE STIX adopted by approximately 40% of U.S. patients by quarter-end and helping bring discontinued patients back to treatment. ACADIA raised its 2026 DAYBUE guidance to $480 million–$510 million.
NUPLAZID sales grew 10% to $183 million, while new patient prescriptions rose 20% year over year. Management said the expanded field force is beginning to contribute and maintained its goal of approximately $1 billion in 2028 NUPLAZID sales.
DAYBUE received a positive CHMP opinion in Europe, with a European Commission decision expected by the end of the third quarter and a planned German launch in early fourth quarter. Management expects Europe to represent less than half of its $700 million 2028 DAYBUE sales target.
The key pipeline catalyst is the phase II RADIANT readout for remlifanserin in Alzheimer’s disease psychosis, now expected in September–October after enrollment of 363 patients. ACADIA has begun phase III screening, but the program remains dependent on demonstrating clinically meaningful efficacy and a supportive safety profile.

ACADIA Pharmaceuticals Stock Up 6.0%

ACAD traded up $1.54 on Tuesday, reaching $27.15. 2,437,594 shares of the company traded hands, compared to its average volume of 1,654,796. ACADIA Pharmaceuticals has a one year low of $19.69 and a one year high of $28.35. The firm has a fifty day simple moving average of $23.83 and a two-hundred day simple moving average of $23.20. The company has a market cap of $4.65 billion, a P/E ratio of 12.34, a price-to-earnings-growth ratio of 17.94 and a beta of 0.81.

Insider Activity

In other news, EVP Elizabeth H.Z. Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $26.13, for a total transaction of $432,660.54. Following the completion of the sale, the executive vice president owned 18,994 shares of the company’s stock, valued at approximately $496,313.22. The trade was a 46.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider James Kihara sold 5,401 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total transaction of $114,393.18. Following the sale, the insider directly owned 24,509 shares of the company’s stock, valued at $519,100.62. This represents a 18.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 26.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ACAD. State Street Corp increased its holdings in ACADIA Pharmaceuticals by 9.0% during the 4th quarter. State Street Corp now owns 7,910,733 shares of the biopharmaceutical company’s stock worth $211,296,000 after purchasing an additional 655,257 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of ACADIA Pharmaceuticals by 4.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,920,974 shares of the biopharmaceutical company’s stock worth $78,019,000 after buying an additional 122,840 shares during the period. Marshall Wace LLP grew its position in shares of ACADIA Pharmaceuticals by 19.8% during the 3rd quarter. Marshall Wace LLP now owns 2,358,881 shares of the biopharmaceutical company’s stock worth $50,339,000 after buying an additional 389,170 shares in the last quarter. First Trust Advisors LP grew its position in shares of ACADIA Pharmaceuticals by 16.8% during the 4th quarter. First Trust Advisors LP now owns 2,270,034 shares of the biopharmaceutical company’s stock worth $60,633,000 after buying an additional 326,882 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of ACADIA Pharmaceuticals by 390.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company’s stock worth $35,187,000 after buying an additional 1,312,426 shares in the last quarter. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ACAD. Citigroup upped their price objective on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Bank of America reiterated a “buy” rating and issued a $14.50 target price on shares of ACADIA Pharmaceuticals in a report on Wednesday, July 29th. Stifel Nicolaus boosted their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a “hold” rating in a research report on Tuesday, July 21st. Canaccord Genuity Group increased their price target on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Royal Bank Of Canada raised their price target on ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Thirteen analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.31.

Get Our Latest Stock Report on ACADIA Pharmaceuticals

About ACADIA Pharmaceuticals

(Get Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.